Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | ERN1 | O75460 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7534038 | 0.85 | AOC3 (0.49) | AOC3CYP19A1SIGMAR1ERN1MEN1 | |
| SCHEMBL7533404 | 0.83 | AOC3 (0.51) | AOC3CYP19A1MEN1KMT2ACHRM1 | |
| Trifluoroacetic Acid SCHEMBL7525401 | 0.79 | AOC3 (0.43) | AOC3 | |
| Trifluoroacetic Acid SCHEMBL7528873 | 0.78 | AOC3 (0.52) | AOC3MEN1KMT2A | |
| SCHEMBL7534604 | 0.77 | AOC3 (0.35) | AOC3CYP19A1SIGMAR1ERN1MEN1 | |
| SCHEMBL7534337 | 0.76 | AOC3 (0.56) | AOC3 | |
| SCHEMBL7527633 | 0.75 | AOC3 (0.48) | AOC3 | |
| Trifluoroacetic Acid SCHEMBL7528189 | 0.74 | AOC3 (0.43) | AOC3MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL11490292 | 0.72 | AOC3 (0.58) | AOC3 | |
| Trifluoroacetic Acid SCHEMBL7532741 | 0.71 | AOC3 (0.48) | AOC3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198189-A1 | Treatment or prophylaxis of Semicarbazide-sensitive amine oxidase (SSAO) mediated complications in mammals including humans | BIOVITRUM AB (SE) | 2002-12-26 | — | — | US | disclosed |
| WO-2002038153-A1 | NEW USE OF 4, 5, 6, 7-TETRAHYDROIMIDAZO-[4,5-C]PYRIDINE DERIVATIVES | BIOVITRUM AB (SE) | 2002-05-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198189-A1 | Treatment or prophylaxis of Semicarbazide-sensitive amine oxidase (SSAO) mediated complications in mammals including humans | AOC3, AOC2, AOC1 | AOC3 1/4885CYP19A1 338/4885SIGMAR1 433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.